We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-19.51%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$201M
AUM Growth
-$42.4M
Cap. Flow
+$13M
Cap. Flow %
6.49%
Top 10 Hldgs %
47.8%
Holding
87
New
12
Increased
27
Reduced
14
Closed
4

Top Buys

Rank Stock Value
1
IBB icon
iShares Biotechnology ETF
IBB
+$4.12M
2
VKTX icon
Viking Therapeutics
VKTX
+$2.14M
3
LOXO
Loxo Oncology, Inc
LOXO
+$1.82M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$1.8M
5
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$1.46M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$1.9M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$1.46M
3
NVAX icon
Novavax
NVAX
+$1.32M
4
KURA icon
Kura Oncology
KURA
+$1.22M
5
IMDZ
Immune Design Corp.
IMDZ
+$1.13M

Sector Composition

Rank Sector Weight
1 Healthcare 88.58%
2 Financials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLCM
76
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$88K 0.04%
3,000
– –
DERM
77
DELISTED
Dermira, Inc.
DERM
$72K 0.04%
10,000
+5,000
+100% +$54.7K
ORMP icon
78
Oramed Pharmaceuticals
ORMP
$167M
$48K 0.02%
+16,000
New +$66.2K
NEOS
79
DELISTED
Neos Therapeutics, Inc
NEOS
$45K 0.02%
27,500
– –
NVAX icon
80
Novavax
NVAX
$1.2B
– –
-35,000
Closed -$1.32M
VIRX
81
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-10,677
Closed -$747K
NTGN
82
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
– –
-50,000
Closed -$427K
IMDZ
83
DELISTED
Immune Design Corp.
IMDZ
– –
-328,500
Closed -$1.13M
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, DAFNA Capital Management held 87 positions worth $201M, down 17% from $244M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management deployed $13M of net new capital in Q4 2018, opening 12 new positions and adding to 27 existing holdings. Its largest new stake was Viking Therapeutics: 179,200 shares worth $1.37M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 89% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $1.9M trimmed.

  • DAFNA Capital Management's largest Q4 2018 buy was Viking Therapeutics: 179,200 shares worth $1.37M.
  • DAFNA Capital Management added most to iShares Biotechnology ETF in Q4 2018, an estimated $4.12M increase.
  • DAFNA Capital Management's biggest Q4 2018 reduction was Immunomedics Inc, cutting an estimated $1.9M.
  • DAFNA Capital Management fully exited Novavax in Q4 2018, selling an estimated $1.32M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $201M portfolio in Q4 2018.
  • DAFNA Capital Management opened 12 new positions and closed 4 in Q4 2018.
  • DAFNA Capital Management's portfolio value fell 17% quarter-over-quarter to $201M.

Based on DAFNA Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.